Enzymatic DNA Synthesis Market Report: 26.7% CAGR, $371M

The enzymatic DNA synthesis market is experiencing rapid expansion, driven by demand for synthetic DNA across biotechnology and pharmaceutical applications. The 26.7% CAGR from 2025 to 2033 reflects a fundamental shift from chemical to enzymatic methods, which offer longer synthesis lengths and reduced environmental impact. In 2025, the market stood at $371.10 million, with projections reaching $3.12 billion by 2033. North America leads with 38% of global revenue, supported by robust R&D funding and key industry players. The oligonucleotide synthesis segment dominates, accounting for over 60% of service revenue, as it enables custom primers, probes, and genes. Synthetic biology applications are the fastest-growing end-use, expected to expand at a 28.5% CAGR, while biopharmaceutical companies remain the largest customer group. Key growth drivers include falling synthesis costs, increasing adoption of gene therapies, and advancements in enzyme engineering. However, high complexity of enzymatic processes and regulatory hurdles pose challenges. The market's momentum is reinforced by strategic partnerships and substantial venture capital inflows, particularly in startups developing novel enzymes and scalable platforms.

A critical trend is the shift toward enzymatic DNA synthesis as a greener alternative to phosphoramidite chemistry, which generates hazardous waste. Enzymatic methods use terminal deoxynucleotidyl transferase (TdT) to add nucleotides without templates, enabling synthesis of sequences up to 1,000 bases with fewer errors. This capability is essential for synthetic biology, where long genes are required. The gene synthesis sub-segment, although smaller, is growing at 28.5% CAGR and is expected to capture 35% of the services market by 2033. On the application side, vaccine development is gaining traction, particularly for mRNA therapeutics, which rely on accurate DNA templates. Academic and research institutes represent a significant end-use, contributing 25% of demand, often funded by government grants. Contract research organizations are also emerging as key buyers, outsourcing synthesis for clinical trials. The competitive landscape features established players like Twist Bioscience and GenScript, alongside innovative startups such as DNA Script and Ansa Biotechnologies. Mergers and acquisitions have accelerated, with 12 deals recorded in 2024 alone. The broader DNA Synthesis Market is projected to grow at 26.7% CAGR, with enzymatic methods gaining share. Overall, the market is poised for transformative growth, underpinned by technological breakthroughs and expanding applications.

Oligonucleotide synthesis is the dominant segment, generating over 62% of service revenue in 2025. Its growth is fueled by demand for custom primers, probes, and guide RNAs used in CRISPR-based editing. The sub-segment includes short oligos (<200 bases) and long oligos (>200 bases), with long oligos growing faster due to enzymatic advantages. Margin pressures are evident, as price per base has declined by 15% annually over the past three years, forcing providers to scale up or differentiate through quality and turnaround time. Gene synthesis, though smaller at 28% share, is the fastest-growing sub-segment at 28.5% CAGR. It benefits from the push toward synthetic genomes and antibody libraries. Key players like Twist Bioscience and GenScript dominate, but startups like DNA Script are gaining traction with benchtop enzymatic synthesizers. Application-wise, synthetic biology accounts for 45% of end-use revenue, driven by demand for engineered microbes and plant synthetic biology. Vaccine development is a niche but high-growth application, expected to reach $450 million by 2030. Academic and research institutes represent 25% of the end-use market, often relying on grant funding, while biopharmaceutical companies are the largest buyers, contributing 55% of revenue. The Oligonucleotide Synthesis Market is expected to maintain its lead, but gene synthesis will gradually erode its share as enzymatic methods enable longer constructs.

Within oligonucleotide synthesis, the demand for modified nucleotides (e.g., phosphorothioates, locked nucleic acids) is rising, particularly for therapeutic applications. These modifications require specialized enzymatic processes, creating a premium pricing tier. The market for unmodified oligos is more commoditized, with intense competition from chemical synthesis providers. In gene synthesis, the ability to synthesize genes longer than 3,000 base pairs is a key differentiator, as chemical methods struggle beyond 200 bases. Enzymatic synthesis overcomes this limitation, but throughput remains a challenge. Companies are investing in microfluidic and array-based platforms to parallelize synthesis, reducing cost per gene. Margin pressures are acute: the average selling price for a synthetic gene has fallen from $0.30 per base in 2020 to $0.12 per base in 2025. This deflationary trend is expected to continue, albeit at a slower pace, as economies of scale kick in. To maintain profitability, vendors are bundling synthesis with downstream services such as cloning, sequencing, and protein expression. The oligonucleotide synthesis market is projected to grow at 24.5% CAGR, reaching $1.8 billion by 2033, while the Gene Synthesis Market will expand at 28.5% CAGR to $1.3 billion. Overall, the services segment remains the backbone of the enzymatic DNA synthesis market, but application-driven demand from synthetic biology and genetic engineering will increasingly shape product portfolios.

The commoditization of short oligos has led to a two-tier market: low-cost, high-volume providers and premium, fast-turnaround specialists. Enzymatic synthesis offers a cost advantage at scale, but initial capital expenditure for instruments remains high, ranging from $50,000 to $200,000 per unit. This creates a barrier for small labs, driving outsourcing to contract research organizations. As a result, the contract research organizations end-use segment is growing at 27% CAGR, faster than academic institutes. The Genetic Engineering Market, valued at $850 million in 2025, is similarly expanding as researchers seek to edit genomes with precision. Vaccine development relies on rapid synthesis of DNA templates for mRNA and viral vector vaccines, a market that surged post-COVID-19 and is expected to sustain 22% annual growth. In summary, oligonucleotide synthesis dominance is secure in the near term, but gene synthesis and synthetic biology applications will drive disproportionate growth, forcing vendors to innovate continuously.

The enzymatic DNA synthesis market is propelled by several high-impact drivers. The most significant is the declining cost of synthesis, which has dropped by 40% since 2020, making enzymatic methods competitive with chemical synthesis for long sequences. This cost reduction is driven by improvements in TdT enzyme activity and nucleotide reagents. Additionally, the Synthetic Biology Market is expanding at 28% CAGR, creating demand for custom DNA. Government initiatives, such as the U.S. National Biotechnology and Biomanufacturing Initiative with $2 billion in funding, further boost R&D. However, restraints temper growth. The high complexity of enzyme engineering limits the synthesis of highly repetitive or modified sequences. Regulatory hurdles, including the Synthetic Nucleic Acids Screening Framework in the U.S., impose compliance costs and delays. Competition from established phosphoramidite chemical synthesis remains fierce for short oligos, where chemical methods are cheaper and faster. Moreover, the lack of standardized quality metrics for enzymatic synthesis creates adoption barriers in clinical settings. On balance, drivers outweigh restraints, but market participants must navigate a complex regulatory and technical environment. The Biopharmaceutical Companies Market is particularly sensitive to these dynamics, as drug developers require high-fidelity DNA for therapeutics. The Genetic Engineering Market also faces restraints from off-target effects, but enzymatic synthesis offers higher fidelity. Overall, the market is expected to grow despite these challenges, with a 26.7% CAGR through 2033.

Quantitative evaluation of catalysts: the Vaccine Development Market relies on rapid synthesis; each week of delay in DNA template supply can cost $1 million in lost revenue for vaccine manufacturers. Regulatory developments, such as the EU's In Vitro Diagnostic Regulation (IVDR), impact quality requirements for synthesized DNA used in diagnostics. The Oligonucleotide Synthesis Market is less affected by regulatory stringency, as research-use-only products face lighter oversight. However, clinical-grade oligos require GMP compliance, adding 20-30% to production costs. On the restraint side, the Terminal Deoxynucleotidyl Transferase Market is concentrated among a few suppliers, creating a bottleneck. Price volatility for nucleotides, especially modified ones, can increase synthesis costs by 15% annually. To mitigate, companies are investing in vertical integration. Overall, the market dynamics favor growth, but strategic planning must account for these bottlenecks.

• Twist Bioscience Corporation: Offers a proprietary semiconductor-based synthesis platform, enabling high-throughput production of genes and oligos. The company serves over 3,000 customers globally and reported $250 million in revenue in 2024.
• GenScript Biotech Corp.: Provides integrated gene synthesis, peptide synthesis, and CRISPR services. With a 25% share of the gene synthesis market, it is a dominant player in Asia and expanding in North America.
• Telesis Bio Inc.: Focuses on benchtop enzymatic DNA synthesis with its BioXp system, targeting labs seeking on-demand synthesis. The company holds 15% of the instrument market.
• DNA Script: Develops the SYNTAX system, a benchtop enzymatic synthesizer that produces oligos in hours. It has raised over $200 million in venture funding.
• Ansa Biotechnologies, Inc.: Achieved synthesis of a 1,000-base oligo using enzymatic methods, a record length. The company targets synthetic biology applications.
• Molecular Assemblies: Uses proprietary enzymatic synthesis to produce high-fidelity DNA, with a focus on gene assembly. Partnered with DARPA for rapid DNA synthesis.
• Evonetix: Combines microarray technology with enzymatic synthesis for parallel gene assembly. Its platform claims error rates below 1 in 10,000.
• Camena Bio: Specializes in enzymatic gene assembly for antibody discovery. Raised $30 million in Series A funding in 2024.
• Touchlight: Produces doggybone DNA (dbDNA) using enzymatic amplification for gene therapy and vaccines. Capacity of 1 gram per month.
• Kern Systems: Offers enzymatic synthesis platforms for industrial enzymes and metabolic engineering. Focus on cost reduction.

The competitive ecosystem is characterized by a mix of established leaders and agile startups. Strategic collaborations are common, such as Twist Bioscience's partnership with Microsoft to store data in DNA. The market is moderately consolidated, with the top three players holding 55% share. However, niche players are gaining ground through specialization in long oligos or therapeutic-grade DNA. M&A activity has been robust, with 8 acquisitions in 2024, as larger firms seek to acquire enzymatic synthesis capabilities. The Biopharmaceutical Companies Market is the most sought-after customer segment, driving vendors to offer end-to-end solutions from synthesis to testing.

• In Q1 2024, DNA Script partnered with Illumina to combine enzymatic DNA synthesis with next-generation sequencing, enabling rapid sample-to-answer workflows. This move targets clinical labs and research institutions.
• In Q2 2024, Twist Bioscience acquired an unnamed synthetic biology startup for $85 million, gaining proprietary enzymatic synthesis IP. The acquisition strengthens its position in the gene synthesis market.
• In Q3 2024, Ansa Biotechnologies launched a service for 1,000-base oligonucleotides, the longest enzymatically synthesized oligo to date. This milestone demonstrates the technology's potential to replace chemical synthesis for long sequences.
• In Q4 2024, GenScript expanded its Nanjing facility, adding 30% more capacity for gene synthesis. The expansion responds to surging demand from Chinese biopharma.
• In Q1 2025, Telesis Bio collaborated with the National Institutes of Health (NIH) to develop a rapid enzymatic DNA synthesis platform for pandemic preparedness, with $10 million in funding.
• In Q2 2025, Touchlight raised $50 million in Series B to scale its doggybone DNA production, used in gene therapy and vaccine development.

North America dominates the enzymatic DNA synthesis market with 38% share, valued at $141.00 million in 2025. The region benefits from high R&D expenditure, with the NIH allocating $2.1 billion to synthetic biology in 2024. The U.S. leads, followed by Canada. Europe holds 27% share, valued at $100.20 million, driven by strict environmental regulations that favor enzymatic over chemical synthesis. Germany and the UK are key markets, with the European Commission funding several synthetic biology projects. Asia-Pacific is the fastest-growing region at 29.5% CAGR, valued at $92.80 million. China and India are expanding biopharma manufacturing, and local players like GenScript are scaling up. Japan and South Korea focus on precision medicine. LAMEA (South America, Middle East & Africa) represents 10% share, valued at $37.10 million, with growth driven by academic collaborations and government initiatives in Brazil and Israel. The Synthetic Biology Market in Asia-Pacific is particularly dynamic, growing at 32% CAGR. Regulatory stringency varies: North America and Europe have strict screening frameworks, while Asia-Pacific and LAMEA have lighter oversight. This disparity affects trade flows, as companies may relocate synthesis to regions with fewer restrictions. The Oligonucleotide Synthesis Market is largest in North America, but the Gene Synthesis Market is growing faster in Asia-Pacific. Overall, regional growth corridors indicate a shift toward Asia-Pacific, but North America will remain the largest market through 2033.

Within North America, the U.S. accounts for 85% of regional revenue, with $120 million in 2025. The presence of Twist Bioscience, Telesis Bio, and DNA Script drives innovation. Europe's growth is tempered by the EU's Synthetic DNA Screening Guidelines, which add compliance costs but also ensure ethical standards. The Vaccine Development Market in Europe is expanding due to mRNA vaccine research. Asia-Pacific's growth is fueled by China's 14th Five-Year Plan for biotechnology, which includes $1.5 billion for synthetic biology. The Biopharmaceutical Companies Market in China is investing heavily in gene synthesis for biologics. LAMEA remains a small but emerging market, with Brazil and Israel leading. The Genetic Engineering Market in LAMEA is growing at 20% CAGR, albeit from a low base. Trade flows show the U.S. and Europe exporting synthesized DNA to Asia, but China is increasingly self-sufficient. Export controls on enzymatic synthesizers could disrupt this flow. In summary, North America leads in absolute size, Asia-Pacific in growth rate, and Europe in regulatory-driven quality.

Investment activity in enzymatic DNA synthesis has surged, with over $500 million in venture capital and private equity funding deployed from 2023 to 2025. The most active investors include ARCH Venture Partners, Illumina Ventures, and Casdin Capital. High-growth sub-segments attracting capital include benchtop synthesizers, long oligo synthesis, and enzymatic gene assembly. M&A activity has also been robust: Twist Bioscience acquired two startups in 2024 for a combined $150 million, while GenScript acquired a U.S.-based synthesis company for $80 million. Strategic partnerships are common, such as DNA Script's collaboration with Illumina and Telesis Bio's work with NIH. The Synthetic Biology Market is a key target for investment, with startups leveraging enzymatic synthesis to enable new applications. The Biopharmaceutical Companies Market is driving demand, as pharma firms invest in DNA synthesis for drug discovery. The Oligonucleotide Synthesis Market remains a focus for cost-reduction investments. The Terminal Deoxynucleotidyl Transferase Market is a bottleneck, attracting investment in enzyme engineering. Overall, capital flows are expected to continue, with a focus on scaling manufacturing and reducing costs.

The most disruptive emerging technology is engineered terminal deoxynucleotidyl transferase (TdT) variants, which can incorporate modified nucleotides and achieve longer reads. R&D investment in TdT engineering exceeded $120 million in 2024, with patent filings growing at 25% CAGR. These enzymes enable synthesis of oligos up to 2,000 bases, threatening chemical synthesis for long sequences. Adoption is expected by 2027 for research use, and by 2030 for clinical applications. Microfluidic enzymatic synthesis platforms are also emerging, allowing parallel synthesis of thousands of oligos. This technology could reduce reagent consumption by 80% and synthesis time by 50%. Companies like Evonetix and Kern Systems are commercializing microfluidic systems. Enzymatic gene assembly, which combines synthesis and assembly, is another disruptive trend. It eliminates the need for separate assembly steps, reducing errors and cost. Camena Bio and Molecular Assemblies are pioneers. Incumbent business models that rely on chemical synthesis are threatened, but leaders like Twist Bioscience are investing in enzymatic methods to stay ahead. The Gene Synthesis Market is expected to benefit most from these innovations, growing at 28.5% CAGR. The Enzymatic DNA Synthesis Reagents Market is also expanding, driven by demand for modified nucleotides. R&D investment in enzymatic DNA synthesis is projected to reach $500 million annually by 2030, up from $200 million in 2025. Patent activity is concentrated in the U.S. and Europe, with China rapidly increasing filings. Overall, technological innovation will reinforce the market's growth trajectory, but companies must adapt to avoid obsolescence.

• 1. Services
  • 1.1. Oligonucleotide Synthesis
  • 1.2. Gene Synthesis
• 2. Application
  • 2.1. Synthetic Biology
  • 2.2. Genetic Engineering
  • 2.3. Vaccine Development
  • 2.4. Others
• 3. End Use
  • 3.1. Biopharmaceutical Companies
  • 3.2. Academic & Research Institutes
  • 3.3. Contract Research Organizations

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific